← All trials
NCT00128557
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2004
- Primary completion
- —
- Completion date
- Dec 1, 2006
- First posted
- —
- Last posted
- —
- Enrollment
- 25000
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- Johns Hopkins UniversityLead sponsor
- Johns Hopkins UniversityCollaborator
- Bill and Melinda Gates FoundationCollaborator
- Canadian International Development AgencyCollaborator
- Johns Hopkins UniversityOverall official - principal investigator
- Johns Hopkins UniversityStudy director
- United States Agency for International DevelopmentCollaborator
- Access Business Group, LLCCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.